This week, the U.S. Preventive Services Task Force published a new draft guideline on breast cancer screening.1 The task force is considered the most rigorous and orthodox authority on the interpretation and application of the medical literature. The panel is widely respected for its expertise in epidemiology, screening, clinical trials interpretation, and structured reviews of... […]
The latest draft guideline by the U.S. Preventive Services Task Force is part of a 50-year controversy over the appropriateness of screening women between the ages of 40 and 49.
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.
Susan G. Komen appointed nine medical and research experts to serve as advisors to the organization.
A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.
While trying to understand what initiates breast cells to become cancerous, researchers at the Vera Bradley Foundation Center for Breast Cancer Research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a new target for breast cancer treatment.
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center shows benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings were presented by first author Arya Mariam Roy during the American Association for Cancer Research annual meeting.
To provide a roadmap for accelerating progress against breast cancer over the next 10 years, an expert panel was convened at the 2022 San Antonio Breast Cancer Symposium to identify the biggest obstacles hindering our ability to cure breast cancer and to propose transformative solutions to address these obstacles.
Researchers from New Century Health and Neighborhood Health Plan of Rhode Island presented findings from their efforts to increase adoption of hypofractionation in breast cancer patients at the National Comprehensive Cancer Care Network conference, on March 31.
Researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators have shown that immature natural killer cells are present in patients with triple-negative breast cancer and likely promote, instead of inhibit, disease progression in this cancer type.
